ReviewFrontiers in immunology2026
The CXCL12-CXCR4 axis in colorectal cancer: immune regulation, metastatic progression, and therapeutic implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selective MicroRNA Dysregulation in IPF-Derived Mesenchymal Stromal Cells Suggests Restricted Regulatory Remodeling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis remains the major cause of mortality in colorectal cancer (CRC) despite continued advances in diagnosis and treatment. Increasing evidence identifies the CXCL12/CXCR4 chemokine axis as a critical driver of CRC progression and metastatic dissemination. Through dynamic interactions between tumor cells and the tumor microenvironment, this axis regulates multiple processes essential for metastasis, including driving migration and invasion, angiogenesis and lymphangiogenesis, and shaping the tumor immune microenvironment through recruitment of immunosuppressive populations, blockade of effector lymphocyte trafficking and function, and modulation of immunosuppressive cytokines including IL-10. In this review, we summarize the molecular mechanisms by which CXCL12/CXCR4 promotes CRC metastasis. These pleiotropic effects are mediated by crosstalk with PI3K/Akt, MAPK/ERK, and Wnt/β-catenin pathways, and are regulated at transcriptional, post-transcriptional, and post-translational levels. Preclinical studies demonstrate that CXCR4 antagonists (e.g., plerixafor, LY2510924) suppress metastasis and, when combined with immune checkpoint inhibitors, can reverse the "cold" immune phenotype of microsatellite-stable CRC. We also discuss recent advances in the regulation of CXCL12/CXCR4 expression, the role of related receptors such as CXCR7, and emerging strategies targeting this axis for therapeutic intervention. Collectively, current evidence supports the CXCL12/CXCR4 axis as a promising biomarker and therapeutic target in metastatic CRC, and further elucidation of its regulatory network may facilitate the development of more effective precision treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.